| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
137,473 |
119,960 |
$7.15M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
74,926 |
67,794 |
$5.69M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
42,909 |
37,632 |
$3.70M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
76,564 |
70,498 |
$3.43M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
29,966 |
27,330 |
$3.40M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
16,311 |
14,764 |
$2.27M |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
10,884 |
1,688 |
$1.93M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
54,433 |
47,808 |
$1.50M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
44,277 |
39,969 |
$1.37M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
16,886 |
15,936 |
$901K |
| 87428 |
|
14,750 |
13,095 |
$358K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
11,376 |
10,055 |
$292K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
12,837 |
11,834 |
$272K |
| 96127 |
|
16,164 |
14,329 |
$267K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
1,509 |
1,429 |
$258K |
| 99051 |
|
22,142 |
20,407 |
$140K |
| 99442 |
|
2,710 |
2,540 |
$102K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
485 |
461 |
$55K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,261 |
5,236 |
$52K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,613 |
4,287 |
$47K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,640 |
1,054 |
$46K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
557 |
522 |
$45K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,242 |
2,615 |
$36K |
| 99384 |
|
239 |
220 |
$29K |
| 99173 |
|
4,578 |
4,235 |
$29K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
437 |
372 |
$23K |
| 87631 |
|
208 |
193 |
$21K |
| 99385 |
|
154 |
141 |
$20K |
| 36415 |
Collection of venous blood by venipuncture |
5,898 |
5,214 |
$16K |
| 94060 |
|
413 |
347 |
$9K |
| 94660 |
|
463 |
391 |
$9K |
| 94729 |
|
436 |
368 |
$9K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
68 |
64 |
$8K |
| 94727 |
|
429 |
362 |
$7K |
| 93000 |
|
489 |
454 |
$7K |
| 87430 |
|
481 |
448 |
$5K |
| 86580 |
|
795 |
727 |
$5K |
| 99386 |
|
28 |
27 |
$4K |
| 94726 |
|
210 |
172 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
33 |
32 |
$4K |
| 99383 |
|
29 |
29 |
$4K |
| 94010 |
|
242 |
206 |
$3K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
23 |
22 |
$3K |
| 90686 |
|
362 |
351 |
$2K |
| 81025 |
|
433 |
412 |
$2K |
| 95115 |
|
288 |
153 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
119 |
102 |
$2K |
| 80305 |
|
237 |
228 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
170 |
160 |
$1K |
| 86618 |
|
107 |
90 |
$1K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
15,092 |
13,651 |
$1K |
| 85014 |
|
460 |
432 |
$892.93 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
35 |
31 |
$723.69 |
| 90715 |
|
30 |
30 |
$706.44 |
| 99454 |
|
162 |
130 |
$590.06 |
| 95117 |
|
53 |
26 |
$472.70 |
| 99457 |
|
87 |
79 |
$301.00 |
| G0454 |
Physician documentation of face-to-face visit for durable medical equipment determination performed by nurse practitioner, physician assistant or clinical nurse specialist |
847 |
691 |
$246.49 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
29 |
24 |
$225.18 |
| 99441 |
|
102 |
97 |
$207.38 |
| 94375 |
|
380 |
332 |
$186.30 |
| 86308 |
|
18 |
18 |
$83.98 |
| 82962 |
|
32 |
28 |
$69.44 |
| 99458 |
|
13 |
13 |
$52.34 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
48 |
47 |
$27.65 |
| 99072 |
|
44,597 |
42,531 |
$27.50 |
| 3078F |
|
34,143 |
30,189 |
$25.00 |
| 3074F |
|
42,211 |
37,194 |
$25.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
16 |
13 |
$23.55 |
| 81002 |
|
14,189 |
12,583 |
$23.05 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12 |
12 |
$8.01 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
134 |
115 |
$3.42 |
| 3077F |
|
1,233 |
1,050 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
13 |
13 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
26 |
24 |
$0.00 |
| 3075F |
|
3,759 |
3,297 |
$0.00 |
| 99000 |
|
681 |
623 |
$0.00 |
| 3079F |
|
12,765 |
11,254 |
$0.00 |
| M1008 |
<50% of total number of a patient's outpatient ra encounters assessed |
17 |
14 |
$0.00 |
| 3080F |
|
1,448 |
1,282 |
$0.00 |